The emergence of resistance to fluoroquinolones in enteric fever despite the pathogen being susceptible by in vitro laboratory results, led to repeated changes in Clinical and Laboratory Standard Institute (CLSI) guidelines for this class of antibiotics to have specific and sensitive interpretative criteria. In 2015, CLSI added pefloxacin disk diffusion criteria as a surrogate marker for fluoroquinolone susceptibility. This study was carried out to evaluate the use of pefloxacin as a surrogate marker for ciprofloxacin, ofloxacin and levofloxacin susceptibility in clinical isolates of Salmonella Typhi and S. Paratyphi A.
developing countries 1, 2 . The treatment continues to pose major therapeutic challenge due to the emergence of antimicrobial resistance in Salmonella enterica serovars Typhi and Paratyphi A, two major pathogens causing enteric fever 3 . For multiple drug resistant strains, which were resistant to first-line drugs i.e. chloramphenicol, amoxicillin and co-trimoxazole, ciprofloxacin became the first line of treatment in enteric fever 4 . However, soon after, the reports of clinical failure to ciprofloxacin therapy started to appear even when the laboratory reports interpreted the strain as susceptible using the Clinical and Laboratory Standard Institute (CLSI) guidelines at that time 5, 6 . The guidelines being used at that time had same interpretative criteria for all members of Enterobacteriaceae. It was reported in a few cases that despite adequate ciprofloxacin treatment the infection relapsed and the subsequent culture during relapse had a higher minimum inhibitory concentration (MIC) to ciprofloxacin, though still sensitive as per the CLSI criteria. Nalidixic acid, the first-generation quinolone correlated with clinical failure to ciprofloxacin 7 and was recommended as a surrogate marker for extraintestinal salmonellae by CLSI in 2009 8 . Later as more data were available, CLSI revised ciprofloxacin breakpoints in 2012 for typhoidal salmonellae 9 and subsequently added other quinolones -ofloxacin and levofloxacin in 2013 10 . In 2015, pefloxacin was added as a surrogate marker for fluoroquinolones susceptibility 11 . The European Committee on Antimicrobial Susceptibility Testing (EUCAST) has recommended the use of pefloxacin disk diffusion as a surrogate marker to determine the susceptibility for ciprofloxacin but does not have a recommendation for ofloxacin and levofloxacin 12 .
Quinolones act on the DNA gyrase and topoisomerase enzymes, inhibit replication and transcription activities and cause fragmentation of DNA 13 . The mechanism of resistance to this class of antibiotics is most commonly associated with the mutations in quinolone resistance determining region (QRDR) of target genes gyrA, gyrB, parC and parE 14 . The isolates with a single mutation in any of the target enzyme show reduced susceptibility to fluoroquinolones, and further accumulation of mutations results in double or triple mutant isolates which have higher MIC to quinolones due to the cumulative effect of mutations 15 . Other mechanisms of resistance are the presence of plasmid-mediated qnr genes and overexpression of efflux pumps but are rarely present in typhoidal salmonellae 16 .
These complex and multiple mechanisms impart resistance and their interplay may be the reason responsible for discordance between the clinical and laboratory results. A single mechanism cannot be specifically attributed to increase in MIC and clinical failure. The advantage of fluoroquinolones is their bactericidal activity, better tolerance and ease of administration. As guidelines for ciprofloxacin for susceptibility in S. Typhi and S. Paratyphi A are being revised frequently and levofloxacin and ofloxacin recommendations are available as MIC breakpoints only, it is ideal to have a surrogate marker which can be used to determine the resistance on the basis of simple disk diffusion method that can be done in a routine clinical microbiology laboratory in low resource setting also.
The present study was carried out to evaluate the present CLSI guidelines 11 in clinical isolates of S. Typhi and S. Paratyphi A from India to determine the use of pefloxacin as a surrogate marker in these isolates.
Material & Methods
A total number of 412 S. Typhi and S. Paratyphi A strains isolated from the enteric fever patients were included in the study. Strains were collected from two centres; 352 strains (303 S. Typhi and 49 S. Paratyphi A) were obtained from All India Institute of Medical Sciences (AIIMS), New Delhi. This included all the strains isolated during 1993-2015 available from archived collection of cryopreserved strains in the department of Microbiology, AIIMS. Sixty strains isolated from Christian Medical College, Vellore, isolated during 2010-2013 were also included. The study was approved by the Institutional Ethical Committees of the participating institutes.
All strains were obtained from blood cultures from the patients suspected to have enteric fever and were preserved as glycerol stocks at -70°C. The stocks were revived and reconfirmed by standard biochemical methods comprising motility, citrate utilization, glucose fermentation, H 2 S production, dulcitol fermentation and decarboxylase reaction 17 . The identification was further confirmed by slide agglutination test with specific antisera (Statens Serum Institute, Copenhagen, Denmark).
Antimicrobial susceptibility testing: Antimicrobial susceptibility testing was done using Kirby-Bauer disk diffusion method 18 for nalidixic acid (30 µg), ciprofloxacin (5 µg), levofloxacin (5 µg), ofloxacin (5 µg) and pefloxacin (5 µg) (Oxoid Ltd., United Kingdom) 11 . MIC was determined for ciprofloxacin, ofloxacin and levofloxacin with E-test as per manufacturer's guidelines (BioMerieux, France). Susceptibility interpretation was done using CLSI guidelines 11 . For result interpretation, intermediate and resistant strains were considered together as resistant. Escherichia coli ATCC 25922 was used as a quality control strain for disk diffusion and MIC determination.
Sequencing of topoisomerase genes: QRDR of gyrA, gyrB, parC and parE genes were sequenced using previous primers as standardized in our laboratory and determined the relation between mutations to these genes and pefloxacin zone diameters 14, 15 .
Statistical analysis: Antimicrobial susceptibility data were analyzed in STATA (Version 11.1, Stata Corp., College Station, Texas, USA). Non-parametric test for trend was performed to determine the temporal patterns of MIC to ciprofloxacin, ofloxacin and levofloxacin. Correlation analysis was done to find out the relationship between MIC trends of ciprofloxacin, levofloxacin and ofloxacin. Correlation coefficients of zone diameter for pefloxacin, ciprofloxacin, ofloxacin, levofloxacin and nalidixic acid were also determined.
Sensitivity, specificity and positive predictive value were determined for the use of pefloxacin disk diffusion as a surrogate marker for susceptibility to ciprofloxacin, ofloxacin and levofloxacin using their respective MICs as gold standard and pefloxacin disk diffusion result was used as test. 
Results

Of
MIC values of ciprofloxacin, ofloxacin and levofloxacin showed a definite increase over time which was significant (P<0.001, P<0.003 and P<0.021, respectively). There was a positive correlation between MIC to ciprofloxacin and ofloxacin having correlation coefficient 0.917 (P<0.001), and also between ciprofloxacin and levofloxacin and between levofloxacin and ofloxacin ( Table I) . Correlation coefficients of zone diameter for ciprofloxacin, ofloxacin, levofloxacin, pefloxacin and nalidixic acid are given in Table II . Scatter plot analysis was done to find out corresponding disk diffusion zones of ciprofloxacin and pefloxacin. The breakpoints for susceptible zones of inhibition for pefloxacin and ciprofloxacin corresponded to each other (Fig. 1) .
Ciprofloxacin susceptible isolates showed a zone of inhibition from 25 to 32 mm using 5 µg pefloxacin disks. However, for pefloxacin susceptible isolates, MIC of ciprofloxacin ranged from 0.002 to 0.38 µg/ml and for pefloxacin resistant isolates MIC range was between 0.125 to 32 µg/ml (Fig. 2) .
Pefloxacin zone diameters and fluoroquinolones MIC results were compared to evaluate the predictive efficacy of pefloxacin as a surrogate marker for fluoroquinolones susceptibility. Of the total 412 isolates tested for pefloxacin susceptibility, The sensitivity, specificity and positive predictive values of pefloxacin as a surrogate marker using ciprofloxacin MIC as a gold standard were 100, 99.5 and 94.4 per cent, respectively. Similarly, the sensitivity, specificity and positive predictive values of pefloxacin as a surrogate marker using ofloxacin and levofloxacin MIC were 100, 99.2 and 91.7 per cent, respectively.
Mechanisms of resistance:
Sequence analysis of gyrA, gyrB, parC and parE revealed the presence of mutations in gyrA and parC genes, but no mutation was detected in gyrB or parE genes. MIC and zone diameter range of mutants and wild type isolates is given in Table III . All isolates with pefloxacin zone of inhibitions ≥24 mm were wild type i.e. did not possess any mutation in QRDR of DNA gyrase or topoisomerase genes.
When compared the susceptibility percentage of two serovars it was observed that fluoroquinolones resistance was significantly higher in S. Paratyphi A. All S. Paratyphi A isolates were in resistance or intermediate category i.e. fluoroquinolone susceptibility in S. Paratyphi A serovar was 0 per cent as per CLSI 2015 11 .
Discussion
Emerging resistance to antityphoidal drugs has been regularly reported from India 19 . Though there has been a decrease in the prevalence of chloramphenicol resistant strains, probably due to the decreased use of chloramphenicol, but an increase in resistance to ciprofloxacin has also been observed from India 20, 21 . Following the ciprofloxacin resistance, ceftriaxone became the drug of choice to treat enteric fever 22, 23 but the reports on clinical failure to ceftriaxone started emerging from Asian region 24 .
Fluoroquinolones have good oral absorption, are bactericidal and are well tolerated. CLSI published evidence-based revision of ciprofloxacin MIC and disk diffusion interpretative criteria in 2012 where susceptibility breakpoints for MIC value has been lowered from ≤1 to ≤0.06 µg/ml, and zone diameter has been increased from ≥21 to ≥31 mm 9 . Studies have shown that the change in CLSI recommendation for ciprofloxacin breakpoints has a significant impact on whether an isolate is classified as susceptible, intermediate or resistant 25, 26 . Subsequently, in 2013, ofloxacin and levofloxacin MIC interpretative criteria were included as ≤0.12 µg/ml for susceptible isolates 10 , followed by the recommendation of the use of pefloxacin as a surrogate marker for fluoroquinolones susceptibility. Pefloxacin showed a sensitivity and specificity of 100 and 99.5 per cent respectively, with a positive predictive value of 94.4 per cent for ciprofloxacin susceptibility. All pefloxacin susceptible isolates were also susceptible to ciprofloxacin except two isolates having intermediate MIC to ciprofloxacin which were susceptible according to pefloxacin disk diffusion test. These variations need to be studied in a larger number of strains across the world.
EUCAST has also recommended the use of pefloxacin as a marker for ciprofloxacin susceptibility 12 , but has no recommendation for ofloxacin and levofloxacin susceptibility. It has been shown that pefloxacin disk diffusion provides a better separation for ciprofloxacin susceptibility than any other disk diffusion, even better than ciprofloxacin itself 27, 28 . In addition, levofloxacin and ofloxacin have only MIC breakpoints and do not have disk diffusion criteria, which makes pefloxacin testing by disk diffusion a convenient method in resource poor settings where MIC determination is not possible 29, 30 . A linear increase was observed in MIC to fluoroquinolones with time. The resistance percentage was higher in S. Paratyphi A than S. Typhi. Based on the molecular mechanism of resistance comparing pefloxacin susceptibility with mutations in the QRDR region of DNA gyrase, it was possible to segregate sensitive wild type from resistant mutant.
A word of caution is that while reporting the susceptibility results for fluoroquinolones in a culture positive enteric fever, pefloxacin should not be reported as it is a surrogate marker only and is not used in clinical practice.
The main limitation of the study was that the strains studied were from hospitals representing two regions of India only. There is a need to generate a larger community-based data to determine the concordance between the interpretation of surrogate marker and clinical outcomes.
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